Regadenoson + Adenosine

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

Oct 1, 2003 → Aug 1, 2006

NCT ID

NCT00208299

About Regadenoson + Adenosine

Regadenoson + Adenosine is a phase 3 stage product being developed by Astellas Pharma for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00208299. Target conditions include Coronary Artery Disease.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00208312	Phase 3	Completed	Apr 1, 2004	Jun 1, 2005	Coronary Artery Disease
NCT00208299	Phase 3	Completed	Oct 1, 2003	Aug 1, 2006	Coronary Artery Disease

Competing Products

20 competing products in Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40